As it has been established that demethylation of lysine 27 of histone H3 by the lysine-specific demethylase JMJD3 increases immune responses and thus elicits inflammation, we hypothesize that inhibition of JMJD3 may attenuate autoimmune disorders.
There is considerable evidence suggesting that epigenetic mechanisms may mediate the development of inflammation by modulating the expression of proinflammatory cytokines and the activation of the transcription factor NF-kb [1e4] . Changes in the epigenetic modification pattern on gene promoters, such as DNA methylation and histone acetylation and methylation, have been involved in the development of some chronic diseases, such as autoimmune and neurodegenerative disorders and cancer [5e9] . JMJD3, a Jumonji C (JmjC) family of histone demethylases, is induced by NF-kb in response to inflammatory stimuli [10] . JMJD3 and its paralog UTX (ubiquitously transcribed X chromosome tetratricopeptide repeat protein), specifically demethylate trimethylated lysine 27 in histone H3 (H3K27me3) [11, 12] , a chromatin modification associated with transcriptional repression [11] . Thus, NF-kB-induced JMJD3 upregulation links inflammation to the control of H3K27me3, a histone modification involved in lineage determination, differentiation and tissue homeostasis [10e12] . Currently, there is great interest in the development of small molecules that are inhibitors of the machinery involved in the generation or removal of post-translational modifications on histones as therapeutic compounds. In 2013, the first selective and potent inhibitor of JMJD3/UTX demethyltransferase activity, GSK-J4, was synthesized by GlaxoSmithKline. Subsequently, two studies have addressed the effect of this drug in immune cells. The first one reported that GSK-J4 attenuates lipopolysaccharide (LPS)-induced proinflammatory cytokine production in primary human macrophages in vitro [13] . The second one addressed the effects of this drug in T-cell differentiation in vitro and that Jmjd3-deficient mice were resistant to the induction of experimental autoimmune encephalomyelitis (EAE) [14] . However, the efficacy of GSK-J4 in inflammation in vivo in the context of autoimmunity has not yet been addressed. Thus, this information persuaded us to study the effect of GSK-J4 in a CD4þ T-cell mediated response in vivo and its relevance in autoimmunity using a murine model of multiple sclerosis (MS).
MS is an autoimmune disorder characterized by the progressive loss of neurological function due to the destruction of the axonal myelin sheath in several areas of the brain and spinal cord, which is mediated mainly by autoreactive CD4þ T cells [15] . Some of the clinical symptoms of the loss of myelin are paralysis, muscle spasms, optic neuritis, and neuropathic pain [16] . The pathological features of MS lesions are blood-brain-barrier permeability, myelin sheath destruction, axonal damage, glial scar formation, and the presence of inflammatory cells infiltrated into the central nervous system (CNS), consisting mostly of lymphocytes [17, 18] . Autoreactive CD4þ T cells displaying inflammatory phenotypes, such as T helper 1 (Th1) cells and Th17 cells, are considered important for MS immunopathogenesis [19e22] . In contrast, regulatory T cells (Tregs) reduce the activity of inflammatory T cells [23e26] . Thus, the balance between Treg and Th1/Th17 cells determines the clinical manifestation of MS. The most widely used animal model for human MS is experimental autoimmune encephalomyelitis (EAE), which induces autoimmunity in mice by immunization with myelin-derived autoantigens [27] . Immunization involves the priming and expansion of peripheral CD4þ T cells bearing inflammatory phenotypes and their subsequent infiltration into the CNS [28] . Importantly, there is evidence indicating that Th1 (IFN-g producers and expressing T-bet) and Th17 (IL-17 producers and expressing RORgt) are not the only inflammatory CD4þ T cells favoring EAE manifestation [29] . It has been determined that CNSinfiltrating CD4þ T cells expressing transcription factors RORgt and T-bet correspond to GM-CSF producers, the most pathogenic CD4þ T-cells in EAE [30, 31] . However, it is clear that T cells are not the only immune cell type involved in MS and EAE pathogenesis, as an increased number of dendritic cells (DCs) has been found in the cerebrospinal fluid of patients with MS, where they display an exacerbated state of maturation [32] . It is thought that in healthy individuals, DCs resident in the CNS play a role in the induction of peripheral tolerance to CNS-derived self-constituents, including myelin. However, due to the abnormal mature phenotype of DCs and their proximity to infiltrated T cells in the CNS of MS patients, it is thought that these DCs play a key role in presenting self-antigens and thus re-stimulating autoreactive T cells infiltrated into the CNS. Importantly, DCs obtained from MS patients are prone to promote Th17 differentiation from naïve CD4þ T cells [33] .
In this study, we investigated the therapeutic potential of GSK-J4 on EAE and explored the immunological mechanisms underlying the effect of the drug. Our results show that systemic treatment with GSK-J4 or adoptive transfer of GSK-J4-treated DCs attenuated the inflammatory response mediated by CD4þ T cells and the manifestation of EAE. Thus, our findings represent new potential therapeutic approaches for autoimmunity. Also, these data present the first evidence about the role of histone demethylases in the development of DCs towards a tolerogenic phenotype.
Materials and methods

Animals
Six-to twelve-week-old mice of the C57BL/6 background were used for all experiments. Wild-type (WT) C57BL/6 and Foxp3-GFP mice were purchased from The Jackson Laboratory (Bar Harbor, ME). All mice were maintained and manipulated according to institutional guidelines at the pathogen-free facility of Fundaci on Ciencia & Vida after approval by the Ethical Review Committee.
Antibodies
Anti-CD3 3, anti-CD28, anti-CD16/32, APC-H7 anti-CD4, APC anti-CD25, PE anti-IL-17A, PECy7 anti-IFNg and PECy7 anti-CD45.1 were purchased from eBioscience (CA, USA). Anti-IL4, anti-IFNg, PE anti-I-A[b], FITC anti-CD40, PE anti-CD86, FITC anti-CD80, UV421 anti-LAP(TGF-b1), APC anti-CD103, PECy7 anti-PDL-1 and UV421 anti-TCRgd were all purchased from BioLegend (CA, USA). AntiH3K4me3 and anti-H3 antibodies were purchased from Abcam (Cambridge, UK). Anti-H3K27me3 and normal rabbit IgG antibodies were purchased from Millipore (MA, USA).
Flow cytometry
The expression of cell surface and intracellular markers on T cells and DCs was determined by FACS analysis after surface staining or intracellular staining with specific anti-mouse antibodies. For cytokine analysis on T cells, cells were stimulated for 4 h at 37 C with 50 ng/mL PMA and 1 mg/mL ionomycin in the presence of 0.01 mg/mL of brefeldin A (BFA) (Sigma-Aldrich). After staining for surface markers, cells were fixed with 1% v/v formaldehyde and permeabilized with 3% w/v BSA and 0.5% w/v Saponin and further stained for intracellular proteins. All data were collected on a FACSCantoII (BD Biosciences) and analyzed with FACS Diva software (BD, New Jersey) or FlowJo software (TreeStar).
Cell isolation and in vitro T-cell differentiation
Naïve CD4þ T cells were obtained from spleens of Foxp3-GFP mice. Splenic CD4þ T cells from Foxp3-GFP mice were enriched by negative selection using the CD4 isolation kit II (Miltenyi Biotec) following the manufacturer's instructions and further purified by sorting for CD4þCD25-Foxp3 -cells using a FACS ARIA II cell sorter (Becton Dickinson, NJ, USA). Dendritic cells from spleens of WT (C57BL/6) mice were enriched by MACS purification using the CD11c microbeads (Miltenyi Biotec). For polarizing experiments, naïve T cells were stimulated with DCs or with plate-bound anti-CD3 and soluble anti-CD28 in the presence or absence 10 or 25 nM GSK-J4 (Tocris Bioscience). For DCs-free stimulations, roundbottom plates were coated with 10 mg/mL of anti-CD3 diluted in PBS and 1 mg/mL soluble anti-CD28 was added to the cultures. For stimulation with DCs, naïve T cells were cultured with DCs at a 5:1 ratio and in the presence of 1 mg/mL anti-CD3 for 4 days. Polarizing conditions were as follows: for iTreg, 5 ng/mL TGF-b, 100 U/mL IL-2, 10 nM retinoic acid, 10 mg/mL anti-IL-4 and 10 mg/mL anti-IFN-g; for Th17, 5 ng/mL TGF-b, 20 ng/mL IL-6, 10 ng/mL IL-1b, 10 mg/mL anti-IL-4 and 10 mg/mL anti-IFN-g; for Th1, 100 U/mL IL-2 and 100 U/mL IL-12.
2.5. Analysis of cytokine mRNA production by real-time RT-PCR Cells were lysed and RNA was extracted using the TRIzol reagent. cDNA (1 mg) was synthesized using oligonucleotide and M- For relative quantification, mRNA expression in each sample was normalized by comparison with the GAPDH mRNA expression using the ddCT method as previously described [34] .
In vitro Treg conversion assays
CD4þFoxp3þ iTreg cells generated in the presence or absence of 10 nM GSK-J4 were purified by cell sorting, stimulated with 1 mg/mL of anti-CD3ε and co-cultured with dendritic cells at ratio 5:1, under polarizing conditions towards Th17 (5 ng/mL TGF-b, 20 ng/mL IL-6 and 10 mg/mL anti-IFN-g) or Th1 (100 U/mL IL-2 and 100 U/mL IL-12).
In vitro suppression assay
Effector T cells (CD4þCD25-) were labeled with 5 mM of CellTrace Violet (Invitrogen, Carlsbad CA) following the manufacturer's instructions and stimulated with 1 mg/mL of antibody against CD3ε (eBioscience) in the presence of CD11cþ splenic DCs at a ratio of 1:2. Labeled Teff cells and CD11cþ were co-cultured for 3d with purified CD4þFoxp3þ iTreg cells generated with or without 10 nM GSK-J4 at ratio 1:0.5; 1:1; 1:2 (Teff:Treg). After 72 h, suppression of proliferation was determined by flow cytometry analysis of CellTrace Violet dilution in a CD45.1þ gate using a FACS Canto II cytometer (BD) and data were analyzed using FACS Diva software (BD).
Pretreatment of DCs and in vitro T-cell differentiation
CD11cþ splenic DCs from C57BL/6 were either left unstimulated or stimulated with 100 ng/mL LPS (Sigma Chemical Co., St. Louis, MO) for 16 h in the presence or absence of 10 nM or 25 nM GSK-J4. After 16 h, these cells were washed, resuspended in fresh media, and co-cultured with naive CD4þ T cells at ratio of 1:5 in the presence of 1 mg/mL of an antibody against CD3ε, under polarizing conditions towards iTreg, Th17 or Th1 as specified above.
Dendritic cell phenotyping
CD11cþ splenic DCs from C57BL/6 mice were either left unstimulated or stimulated with 100 ng/mL LPS for 16 h in the presence or absence of 10 nM or 25 nM GSK-J4. After 16 h, the cells were incubated for 30 min at 4 C with different combinations of the following antibodies: anti-I-A[b], anti-CD40, anti-CD86, anti-CD80, anti-LAP (TGF-b1), anti-CD103 and anti-PDL-1. Fc block (BD Biosciences Pharmingen) was used to block nonspecific binding to Fc receptors. These markers were analyzed by flow cytometry using a FACS Canto II cytometer (BD) and data were analyzed using FACS Diva software (BD).
Cytometric bead array
For cytokine secretion, culture supernatants were collected from CD11cþ splenic DCs from WT mice cultivated for 16 h as indicated. Cytokine production was analyzed using the Mouse Th1/Th2/Th17 Cytokine Kit following the manufacturer's instructions (BD Biosciences).
Western blot
CD11cþ DCs were washed twice with cold phosphate-buffered saline (PBS) and then lysed in RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% Na deoxycholate, 1% NP40) supplemented with a protease inhibitor cocktail (Sigma-Aldrich, USA). Protein concentration of lysates was determined using the Bradford assay (Pierce, Rockford, IL, USA). Equal protein amounts of cell lysates were loaded onto SDS gels and subjected to SDS-PAGE. The separated proteins were transferred onto PVDF membranes and then analyzed by Western blotting using anti-H3K27me3, antiH3K4me3, anti-H3, anti-JMJD3, anti-EZh2 and anti-b-actin antibodies.
Chromatin immunoprecipitation and real time PCR
After cell sorting, CD11cþ DCs were fixed with 1% formaldehyde for 10 min. The reaction was quenched with 0.125 M glycine for 5 min, and cells were washed twice with PBS, resuspended in cell lysis buffer (10 mM Tris-HCl pH 8.0, 10 mM NaCl, 0.2% v/v NP-40, and a protease inhibitor cocktail) for 10 min, and then resuspended in nuclear lysis buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 1% w/v SDS, and a protease inhibitor cocktail). Lysates were diluted twice in sonication buffer (50 mM HEPES pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% v/v Triton X-100, 0.1% w/v deoxycholic acid, 0.1% w/v SDS, and a protease inhibitor cocktail) and then sonicated six times for 5 min on ice to high power with a Bioruptor Plus. Samples were precleared with rabbit IgG and protein A agarose (Millipore). Precleared samples (3 mg) were taken as input control and for ChIP reactions, which were performed overnight at 4 C with 1 mg of anti-H3K27me3, 1 mg of anti-H3K4me3 or 1 mg of rabbit IgG. Immunocomplexes were isolated with protein A agarose and washed twice with sonication buffer, once with wash buffer (500 mM LiCl, 100 mM Tris-HCl pH 8.0, 1% v/v NP-40, and 0.1% w/v deoxycholic acid), and once with TE (50 mM Tris-HCl pH 8.0 and 2 mM EDTA). Samples were then eluted with 100 ml of the immunoprecipitation elution buffer (50 mM NaHCO3 and 1% w/v SDS), and the cross-link was reversed after incubating the samples at 65 C O/N with 10 mg RNAse and 200 mM NaCl. Finally, the samples were treated with 1 mg/mL proteinase K and the DNA isolated by DNA Clean and Concentrator kit (Zymo Research). For quantification of the immunoprecipitated DNA, KAPA SYBR FAST (KAPA Biosystems) was used according to the manufacturer's instructions. Immunoprecipitated DNA was quantified by creating a line of best fit from a standard curve using serial dilutions of genomic template DNA to allow normalization of primer sets. Primers for the IL-6 and TGF-b1 promoters were as follows:
IL-6 forward, 5 0 -CCCACCCTCCAACAAAGATT-3 0 , IL-6 reverse, 5 0 -GCTCCAGAGCAGAATGAGCTA-3 0 , TGF-b1 forward, 5 0 -GGCTTTAGTAGTGCTCCGCC-3 0 and TGF-b1 reverse, 5 0 -GGGGGCACTGTCTTCATCT-3 0 . PCR was carried out for 40 cycles with 95 C for 10 s (melting), 59 C for 5 s (annealing) and 72 C for 5 s (extension).
Generation of DCs
Bone marrow-derived DC precursors from WT mice were prepared as previously described [35] . Briefly, DC precursors were grown in RPMI 1640 medium (Hyclone, Logan, UT) supplemented with 5% heat-inactivated FBS (Biological Industries, Beit Haemek, Israel) and 10 ng/mL recombinant mouse GM-CSF (PeproTech, Rocky Hill, NJ). On day 5, differentiation of DCs was routinely assessed obtaining !90% CD11cþ cells. In some experiments, day 5 DCs were pulsed either with DMSO (vehicle-treated DCs) or with 10 nM GSK-J4 (GSK-J4-treated DCs) for 18 h and used for further experiments.
EAE induction and evaluation
Six-to eight-week-old female C57BL/6 WT mice were injected by subcutaneous injection (s.c.) with 50 mg myelin oligodendrocyte glycoprotein 35e55 peptide (pMOG; Genetel Laboratories, Madison, WI) emulsified in Complete Freund's Adjuvant (CFA) (Invitrogen) supplemented with heat-inactivated Mycobacterium tuberculosis H37 RA (Difco Laboratories, Detroit, MI). In addition, mice received intraperitoneal injection (i.p.) of 500 ng of pertussis toxin (Calbiochem, La Jolla, CA) on days 0 and 2. Clinical signs were assessed daily according to the following scoring criteria: 0, no detectable signs; 1, flaccid tail; 2, hind limb weakness or abnormal gait; 3, complete hind limb paralysis; 4, paralysis of fore and hind limbs; and 5, moribund or death. A stock solution of GSK-J4 of 42 mg/mL (100 mM) was prepared in dimethyl sulfoxide (DMSO) to preserve stability. Before injection, the stock solution was diluted 1/ 10 with ethanol (DMSO: ethanol, 1:10 v/v) and brought to a final concentration of 140 mg/mL in PBS. In systemic drug evaluation experiments, each mouse received daily i.p. injections (from days 0e5) of 100 mL of this solution containing 14.0 mg of the GSK-J4 (equivalent to 0.56 mg/kg of the drug). Control mice received 100 mL of the vehicle during the same period. In other EAE experiments, 10 6 bone marrow-derived DCs from WT mice were treated with GSK-J4 or vehicle alone for 16 h, pulsed with 5 mg/mL of pMOG for 4 h and then transferred i.v. into WT C57BL/6 recipient mice 14 and 7 days before EAE induction [34] . In other adoptive transfer EAE experiments, CD4þFoxp3þ Treg cells generated in the presence or absence of 25 nM GSK-J4 were purified by cell sorting and then 0.75 Â 10 6 transferred i.v. into WT C57BL/6 recipient mice 1 day before EAE induction.
Preparation of CNS mononuclear cells
Mice were perfused through the left cardiac ventricle with cold PBS. The brain and spinal cord were dissected, and CNS tissue was cut into small pieces and digested with collagenase D (2.5 mg/mL; Roche Diagnostics) and DNaseI (1 mg/mL; Sigma) at 37 C for 45 min. Digested tissue was passed through a 70-mm cell strainer obtaining a single cell suspension that was subjected to centrifugation in a Percoll gradient (70%/30% v/v). Mononuclear cells were removed from the interphase and resuspended in culture medium for further analysis.
Statistical analysis
Data are presented as mean ± SEM and P values were analyzed using the Student's t-test or one-way ANOVA followed by Dunnett's test using Prism (GraphPad software). In some cases, P values were analyzed from ManneWhitney rank sums two-tailed U test by using GraphPad Prism software. ns, no significant; statistically significant values are expressed as *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Results
GSK-J4 treatment inhibited the development of EAE in C57BL/6 mice
Based on previous studies demonstrating the in vitro potential of GSK-J4 to restrain the inflammatory response of macrophages [13] , to affect T-cell differentiation and that Jmjd3-deficient mice were resistant to the induction of experimental autoimmune encephalomyelitis (EAE) [14] , we address the question of whether this drug exerts a therapeutic effect in vivo in the context of autoimmunity. For this purpose, we use the mouse model of MS, the EAE. Accordingly, we immunized C57BL/6 wild-type mice with MOG peptide emulsified in CFA as previously described [34] , followed by daily intraperitoneal injections (i.p.) of GSK-J4 or vehicle for 5 days after EAE induction (Fig. 1A) . Then, we compared the susceptibility of untreated and GSK-J4-treated mice to develop the disease. The results show that administration of GSK-J4 significantly reduced the severity of the disease when compared with control mice (maximum severity of 2.13 ± 1.13 in GSK-J4-treated mice versus 4.25 ± 1.04 in control mice, Fig. 1B and C) . Additionally, GSK-J4 treatment delayed the onset of the disease compared with untreated mice (onset of 18.14 ± 2.79 in GSK-J4-treated mice versus 15.50 ± 2.27 in control mice, Fig. 1 B and C) . In addition to the post-induction treatment of EAE with GSK-J4, we also tested the therapeutic potential of this drug by administrating it in a postonset regime. For this purpose, we injected GSK-J4 or the vehicle i.p. daily for five consecutive days starting the day after the onset. Strikingly, the results show that even when administrated after the onset, GSK-J4 exerted a therapeutic effect in EAE manifestation (Fig. S1 ). These data demonstrate that systemic administration of a highly selective inhibitor of H3K27m3 demethylases exerts a therapeutic effect attenuating EAE development and progression. 
GSK-J4 EAE Induction
GSK-J4 increases Treg generation and improves their phenotypic stability and suppressive function through its action on DCs
Considering the pivotal role of pro-inflammatory Th1 and Th17 cells, as well as the anti-inflammatory effects of Tregs on EAE development [19e26], we next investigated the role of GSK-J4 on the polarization of naïve CD4þ T cell to these different subsets in vitro. For this purpose, naïve CD4þ T-cells (CD4þCD25-Foxp3-) purified from C57BL/6 Foxp3-GFP mice were cultured under Th1, Th17 or Treg polarizing conditions for 4 days in the presence of splenic DCs plus anti-CD3 in the presence or absence of GSK-J4. Intracellular expression of IFN-g, IL-17A, and Foxp3-GFP was assessed by FACS, as indicators of Th1, Th17 and Treg differentiation, respectively. Interestingly, the results showed that GSK-J4 treatment increased the production of Treg cells from 35.4% to 47.8% and 53.7% in the presence of 10 and 25 nM of GSK-J4, respectively ( Fig. 2A) . Conversely, GSK-J4 had no effect on the generation of Th17 or Th1 cells ( Fig. 2B and C; Fig. S2 ).
Since tolerogenic DCs can favor the differentiation of naive CD4þ T-cells into Tregs, we wondered whether the GSK-J4-mediated potentiation of Treg differentiation observed in cocultures was due to a direct effect on T cells or, alternatively, was this drug indirectly acting through an effect on DCs. To address this question, we generated Tregs in the absence of DCs using anti-CD3 and anti-CD28 to stimulate T-cells. As seen in Fig. 3A , GSK-J4 did not alter the differentiation of Tregs in the absence of DCs, suggesting that the drug was acting on DCs rather than directly on naïve T cells. To confirm this idea, splenic DCs were preincubated with GSK-J4 for 16 h, washed and then tested for their ability to promote Treg differentiation. Pretreatment of DCs with 10 or 25 nM GSK-J4 resulted in an increased Treg differentiation of 9% and 18%, respectively, when compared with Treg generation in the absence of the drug (Fig. 3B) . Moreover, when DCs were exposed to lipopolysaccharide (LPS), a proinflammatory glycolipid, Treg differentiation was reduced (Fig. 3B) . Nevertheless, when DCs were exposed to GSK-J4 in the presence of LPS, the drug showed a stronger effect favoring Treg differentiation (Fig. 3B) . Thus, together these data strongly support the idea that GSK-J4 acts on DCs, but not directly on CD4þ T-cells, in the potentiation of Treg generation.
It has been suggested that Foxp3þ Treg cells might become unstable under certain inflammatory conditions and might adopt a phenotype characteristic of effector CD4þ T cells [36] ; therefore, we tested the effect of GSK-J4 on Treg stability and plasticity. For that purpose, naïve T cells were polarized toward a Treg phenotype for 4 days in the presence or absence of GSK-J4 and the resulting CD4þFoxp3þ Treg cells were purified by cell sorting (Fig. S3) . These cells were further co-cultured with splenic DCs under Th1 or Th17 polarizing conditions for an additional 4 days and analyzed for IFNg, IL-17A and Foxp3-GFP expression. As shown in Fig. 4 , GSK-J4 reduced the number of Treg converting to Th17 or Th1, while at the same time it increased the proportion of T cells that retained Foxp3 expression. Therefore, our data show that Tregs generated under GSK-J4 treatment are more stable and less susceptible to convert towards Th1 or Th17 proinflammatory phenotypes.
Finally, to determine if GSK-J4 affected the suppressive capacity of Treg cells, the proliferation of responder effector CD4þ T cells was assessed following polyclonal stimulation with splenic DCs plus anti-CD3 in the presence of varying ratios of isolated CD4þFoxp3þ Treg cells generated in presence or absence of GSK-J4. Taken together, these results show that GSK-J4 acts upon DCs promoting the differentiation of Treg cells, improving Treg stability and suppressive capacities, without affecting the differentiation of Th1 and Th17 cells.
GSK-J4 impairs DC maturation while inducing tolerogenic markers in vitro
Dendritic cells are capable of modulating the outcome of the immune response depending on their maturation state, resulting in T-cell-mediated immunity accompanied by the production of proinflammatory cytokines or in tolerance mediated by Tregs. Because our previous results showed that GSK-J4 promotes DCdriven Treg differentiation, we investigated whether the drug affected the maturation state of DCs. DCs cultured with medium alone or LPS were used as controls. As expected, LPS, a stimulator of DC maturation, increased the percent and surface expression of CD80, CD86, and MHCII (Fig. S4) on DCs. When analyzing DCs incubated in the presence of GSK-J4, we found that the drug significantly decreased the population of CD80 þ and CD86 þ DC population (Fig. 6A) . When tested in combination with LPS, GSK-J4 significantly reduced the CD80 and CD86 mean fluorescence intensity (MFI) on DCs (Fig. 6A) . However, no differences were observed in the expression or MFI of MHCII and CD40 (Fig. 6A) . These data indicate an anti-maturation effect by GSK-J4 on DCs. To further characterize the changes on DCs upon GSK-J4 treatment, we analyzed the expression of surface markers involved in the induction of suppressive response. GSK-J4 significantly increased the CD103þ and TGF-b1þ populations, while decreasing the PDL-1þ population in DCs or LPS-DCs (Fig. 6B) , although no changes were observed in the MFI of any these markers, further supporting the tolerogenic effect of GSK-J4. Finally, we monitored cytokine secretion by GSK-J4-treated DCs. As expected, LPS increased IL-6, IFN-g and TNF production by DCs, whereas 25 nM GSK-J4 showed a strong inhibitory effect on the secretion of these proinflammatory cytokines (Fig. 6C) , showing a similar IFN-g profile of expression to that of immature DCs (not exposed to LPS) (Fig. 6C) . Collectively, these results indicate that GSK-J4 prevents DC maturation and leads to a tolerogenic population of DCs, thus explaining its role in inducing the generation of Tregs.
GSK-J4 modifies the methylated status of histone H3 on the promoter of IL-6 and TGF-b1 in DCs
The observed induction of a tolerogenic phenotype in DCs by GSK-J4 treatment raised the question of whether GSK-J4 was regulating the methylation status of histone H3 in DCs. For this purpose, we incubated DCs in the presence or absence of GSK-J4 and LPS and then the methylation status of repressive (H3K27me3) and permissive (H3K4me) markers on histone H3 were analyzed by western blot. GSK-J4 increased the global levels of H3K27me3 in DCs and LPS-DCs, without affecting the global levels of H3K4me3 (Fig. 7A) . We then evaluated the levels of enzymes involved in the methylation and de-methylation of H3K27 in DCs. Our results show that neither Ezh2 (methylase) [37] nor JMJD3 (demethylase) were affected by the drug as determined by western blot. These results suggest that GSK-J4 inhibits H3K27me3 demethylase activity on DCs.
We then analyzed in DCs the methylated status of histone H3 at the IL-6 and TGF-b1 promoters, two genes involved in the development of Treg, by chromatin immunoprecipitation (ChIP). GSK-J4 treatment led to higher H3K27me3 (repressive) and reduced H3K4me3 (permissive) levels on the IL-6 promoter in DCs as well as on LPS-DCs (Fig. 7B) . On the other hand, upon GSK-J4 treatment, H3K27me3 levels were reduced and H3K4me3 levels were increased on the TGF-b1 promoter in both DCs and LPS-DCs (Fig. 7C) . These data correlate with IL6 secretion and TGF-b1 expression (Fig. 6) .
Collectively, these data support the idea of a role of histone demethylase activity in the differentiation of DCs and confirm that GSK-J4 treatment induces a tolerogenic phenotype in DCs by changing the ratio of H3K27me3 and H3K4me3 at specific gene promoters.
GSK-J4 pretreated DCs confer protection to EAE after adoptive transfer
The data presented so far show that DCs are modulated by GSK-J4 in vitro; however, to establish the role of DCs in GSK-J4-mediated immunoregulation, we investigated whether GSK-J4-treated DCs can confer protection after adoptive transfer in the EAE model. For this purpose, we used pMOG-pulsed bone marrow-derived dendritic cells (BMDCs) from C57BL/6 mice, cultured with or without GSK-J4, washed and adoptively transferred to C57BL/6 mice prior to EAE induction. Two doses of 1 Â 10 6 DCs per mouse were used.
After EAE induction, mice adoptively receiving in vitro GSK-J4-treated DCs had significantly lower clinical scores than vehicletreated DCs (Fig. 8A ). This result indicated that DCs previously exposed to GSK-J4 are able to mediate protection from autoimmunity in vivo.
Because of the pivotal role of CNS-infiltrating Th1, Th17, and Treg CD4þ T cells in the outcome of EAE [19e26], we examined the functional phenotypes of CD4þ T cells infiltrating the CNS at the peak of the disease. At day 20 after disease induction, we isolated the infiltrating mononuclear fraction from the spinal cords and brains of mice into which were transferred either vehicle-treated or GSK-J4-treated DCs (see Materials and Methods for more details). Decreased frequencies of two pathogenic CD4þ T-cell populations that infiltrated the CNS were observed, namely IFN-g and IL-17 double producers and GM-CSF producers, while no significant differences were observed in the frequencies of Th1 or Th17 cells (Fig. 8B) . Surprisingly, no differences were detected in the levels of infiltrating Tregs (CD4þFoxp3þ) or in the expression of markers involved in their suppressive activities (Fig. 8C and D) . Moreover, no differences were found in the infiltration of CD8þ or gdT cells (Fig. S5) . Given the fact that no differences were detected in the levels of infiltrating Tregs, we further investigated the in vivo suppressor activity of Tregs generated in the presence of GSK-J4 by adoptive transference of Tregs in EAE mice. As seen in Fig. 8E , GSK-J4-generated Tregs reduced the severity of the disease better than Tregs. These data showed GSK-J4-treated Tregs show a higher suppressor capacity than Tregs in vivo.
Taken together, these data suggest that GSK-J4-treated DCs are able to modulate the development of the autoimmune response in vivo such as in EAE, by reducing the frequency of pathogenic GM-CSF and IFN-g/IL-17 double producer cells infiltrating the CNS and enhancing the suppressive activity of Tregs.
Discussion
The demethylase JMJD3 is crucial for the regulation of the expression of several genes involved in inflammatory signaling pathways [38] . A number of demethylase inhibitors belonging to the Jumonji C family have been synthesized, but they lack specificity [39] , with the exception of GSK-J4/J1 [40, 41] . According to Kruidenier and collaborators, GSK-J1/GSK-J4 is the most specific inhibitor yet synthetized for the members of the KDM6 subfamily JMJD3 and UTX [13] . Although a more refined study showed that GSK-J1/GSK-J4 inhibits to a lesser extent the H3K4me2/me3 demethylase KDM5 subfamily members [40] , GSK-J4 remains the most useful tool for studies involving inhibition of JMJD3 demethylase activity [41] . GSK-J4 was reported to attenuate lipopolysaccharide (LPS)-induced pro-inflammatory cytokine production in primary human macrophages in vitro [13] and recently, its effects on T-cell differentiation have been reported in vitro [14] . However, the efficacy of GSK-J4 in inflammatory or autoimmunity settings in vivo and its effects on dendritic cells in the context of inflammation have not been reported. Consequently, in the present study, we tested the effect of GSK-J4 in an inflammatory setting in vivo, more specifically on EAE and its effects on T cells and dendritic cells in vitro and in an inflammatory context. The results showed herein that GSK-J4 ameliorated the EAE and induced a tolerogenic phenotype in DCs by changing the ratio of H3K27me3 and H3K4me3 on specific promoters. Also, GSK-J4-treated DCs promoted the generation, stability, and suppressive functions of induced Tregs. Together, these data suggest that GSK-J4 could be used to treat autoimmune diseases such as MS. Moreover, these data are the first evidence in support of a role for a histone demethylase in the differentiation of DCs towards a tolerogenic phenotype. Specifically, H3K27me3 demethylase activity would act as a negative regulator of DC differentiation towards a tolerogenic phenotype and inhibition by GSK-J4 would promote a tolerogenic phenotype on DCs by changing the ratio of repressive (H3K27me3) and permissive (H3K4me3) markers at specific gene promoters.
When GSK-J4 was administered to mice after EAE induction, we not only observed a significant reduction in the clinical signs of the disease but also a delay in its onset. Because many cell types have Fig. 7 . GSK-J4 modifies the levels of H3K27me3 and H3K4me3 associated to promoters of inflammatory and anti-inflammatory genes in DCs. CD11cþ splenic DCs from C57BL/ 6 mice were either unstimulated or stimulated with 100 ng/mL LPS in the presence or absence of 25 nM GSK-J4 for 16 h. Total protein extracts from DCs and LPS-DCs treated with GSK-J4 were used to detected H3K27me3, H3K4me3, JMJD3 and Ezh2 by western blotting. Histone H3 and beActin were used as loading control (A). Chromatin Immunoprecipitation (ChIP) assays were performed on DCs and LPS-DCs treated in presence or absence of GSK-J4 using specific antibodies to H3K27me3, H3K4me3 and rabbit isotype-matched immunoglobulin G (IgG), as control. Association of H3K27me3 or H3K4me3 to the promoters of IL-6 (B) and TGF-b1 (C) genes was quantified by qPCR by using specific primers after immunoprecipitation. PCR products were normalized to the input DNA and histone H3 levels. Values represent mean ± SEM from six independent experiments. ns, no significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001 as determined by two-tailed paired Student's t-test.
been involved in the development of EAE, including proinflammatory Th1 and Th17 cells and anti-inflammatory Treg cells, we first analyzed the effect of the drug on the differentiation of these CD4þ T-cell subsets from naïve T cells. It has been reported that JMJD3 is involved in the differentiation of several cell types, including macrophages and CD4þ T-cell subsets [42e44]. JMJD3 has a role in Th1 differentiation by promoting the activation of hallmark Th1 genes in a demethylase-dependent manner [45] , while it is induced on Th17 cells after TCR stimulation, binding to Rorc, Il17a, Il17f, and Il22 genes and promoting their activation also in a demethylase-dependent manner [14] . Moreover, an alternative non-demethylase function has already been described for JMJD3 whereby it induces the activation of several hallmark Th1 genes, including Ifng, by acting as a bridging protein between T-bet and the SWI/SNF chromatin remodeling complex, which in turn disrupts the histone-DNA interaction [46] . Also, JMJD3 controls Th17 differentiation in a demethylase-independent manner through its interaction with transcriptional factors to CNS2, a non-coding sequence that controls the expression of IL-17A [47] . However, in our setting, GSK-J4 did not alter the differentiation of proinflammatory Th1 or Th17 cells in vitro. One explanation is that the expression of IFN-g and IL-17A could be mainly regulated in a demethylase-independent manner; thus, the GSK-J4-mediated inhibition of the demethylase would not have significant effects on the differentiation of these CD4þ T-cell subsets. Moreover, it has been shown that GSK-J4 affected CD4þ T-cell differentiation; nevertheless, the authors used a high concentration of drug and T cells were stimulated with anti-CD3 and anti-CD28 [14] . Another possible explanation is that DCs are more sensitive than CD4þ T cells to the effect of GSK-J4 at a dose of 25 nM. However, these possibilities are not exclusive and therefore, one or both of them could explain why Th1 and Th17 differentiation remained unchanged in vitro when using 10 or 25 nM GSK-J4.
GSK-J4 significantly increased the differentiation of antiinflammatory Treg cells ( Fig. 2A) , which could explain, at least in part, the observed beneficial effects on EAE. The mechanisms by which the promotion of Tregs occurs are not yet fully understood, but they involve a direct effect of GSK-J4 on the maturation status of DCs (Fig. 3) , which in turn promotes the generation of Tregs. Mature or proinflammatory DCs express higher levels of class II major histocompatibility complex and costimulatory B7 molecules, whereas the immature/semi-mature (tolerogenic) phenotype displays an intermediate expression of costimulatory B7 molecules [48] . Also, mature DCs secrete inflammatory cytokines, such as IL-12, IFN-g, IL-4, IL-1b, IL-17, or TNF [49e54], whereas tolerogenic DCs secrete inflammatory cytokines at lower levels or not at all [55] . Our data show that GSK-J4 changes the phenotypic profile of DC in favor of a tolerogenic state (Fig. 6) . Interestingly, our results show that GKS-J4-treated DCs are resistant to maturation in response to "danger signals" such as LPS (Fig. 6 ) and that they induce Treg differentiation in an inflammatory context (Fig. 3B) , two of the most important features of tolerogenic DCs [56] . These lines of evidence show that inhibition of demethylase is important in the development of DCs towards a tolerogenic phenotype. Furthermore, GSK-J4 decreased the expression of PDL-1 together with CD80 and CD86 on DCs. The maturation status of DCs defines the profile of activation of T cells [57] . Functionally, mature DCs stimulate the differentiation of CD4 T cells towards Th1, Th17, and Th2 cells [58] , while tolerogenic DCs are mediators of T-cell tolerance, by several mechanisms including the promotion of Treg differentiation from naïve T cells, which in turn induce a suppressive environment [57] . Thus, the anti-maturation or tolerogenic effect of demethylase inhibition by GSK-J4 on DCs could explain the increased Treg differentiation observed under GSK-J4 treatment in vitro. Interestingly, GSK-J4 not only promoted the generation of Tregs in vitro but also increased their suppressive capacity (Fig. 3) and stability, making them less prone to convert to Th1 or Th17 cells (Fig. 4) . Moreover, it has been shown that DCs from the cerebrospinal fluid of patients with MS have an exacerbated state of maturation [32, 33] thus, in vivo GSK-J4 could be causing reversion to this state in EAE, explaining the beneficial effects of the drug in this inflammatory setting. The role of histone demethylase activity in DC function has not been studied so far. Although a number of demethylase inhibitors belonging to the Jumonji C family have been synthesized, they have proven to have very low specificity [39] . However, GSK-J4, a JMJD3 and UTX inhibitor, has been shown to be specific for these enzymes [13, 40, 41] and thus remains the most useful tool for studies involving inhibition of JMJD3 demethylase activity. Our data showed that the GSK-J4-dependent demethylase activity inhibition induced global level H3K27me3 enrichment in DCs with no changes in H3K4me3, as expected. Under inflammatory conditions, JMJD3 demethylase activity decreased H3K27me3 levels of the IL-6 gene promoter and mediated IL-6 expression in endothelial cells [59] . Our ChIP results showed that LPS increased H3K4me3 without changing H3K27me3, while GSK-J4 treatment increased the H3K27me3 levels of the IL-6 promoter in DCs and at the same time, LPS-DCs reduced the H3K4me3 levels in DCs and LPS-DCs, as expected. These ChIP data, together with the results of IL-6 secretion, suggest that JMJD3 could directly regulate IL-6 expression in an H3K27me3 demethylase-dependent manner in DCs, likely in the same way as in endothelial cells under inflammatory conditions, whereas GSK-J4 treatment induced transcriptional silencing by Polycomb repressive complexes PCR2 and PCR1 [60] on the IL-6 gene promoter in DCs. On the other hand, our ChIP results showed that GSK-J4 treatment in DCs reduced H3K27me3 and increased H3K4me3 levels on the promoter of the TGF-b1 gene (Fig. 7B ). JMJD3 interacts with several transcriptional factors, such as Smad3, as well as key components of the H3K4 methyltransferase complex, such as Ash2L, and even JMJD3 is required to interact with Smad3-AshL2 and form a stable complex, Smad3-Ash2L-JMJD3, wherein JMJD3 controls Smad3 target gene expression via interaction with factor such as Ash2L and binding to promoter regions to active genes [10, 44] . Interestingly, TGF-b1 is a Smad3 target gene and the Smad3 transcriptional factor is necessary for TGF-b1 expression in DCs [61] . Our results for H3K27me3 and H3K4me3 levels on the TGF-b1 promoter by ChIP and TGF-b1 expression by FACS suggest that the inhibition of H3K27me3 demethylase activity by GSK-J4 promotes H3K27me3 demethylaseindependent activity and thus alters methylation status on histone H3 at lysine 27 and lysine 4 on the TGF-b1 gene promoter in DCs. It is likely that GSK-J4 treatment could stimulate activity and/or the formation of a complex such as Smad3-Ash2L-JMJD3, which promotes TGF-b1 expression by increasing H3K4me3 and decreasing H3K27me3 levels on the TGF-b1 gene promoter in DCs.
Our results also showed that prophylactic adoptive transfer of DCs treated ex vivo with GSK-J4 ameliorates EAE symptoms (Fig. 8A) . Interestingly, the attenuated severity of EAE manifestation was associated with a decreased frequency of two important pathogenic CD4þ T-cell populations known to infiltrate the CNS in this pathology [29e31], such as IFN-g/IL-17 producers and GM-CSF producers (Fig. 8B) . In this regard, it has been described that irrespective of the T-helper phenotype, GM-CSF-producing CD4þ T cells are the pathogenic CD4þ T cells involved in EAE [29] . The production of both RORgt and T-bet are necessary for the production of GM-CSF and thereby for the manifestation of a pathogenic Th17 phenotype [29e31, 62, 63] . It is noteworthy that the coexpression of T-bet and RORgt could result in the co-production of IFN-g and IL-17 by these cells, which could correspond to the IFN-gþIL-17þCD4þ T-cell population observed decreased in the CNS of EAE mice injected with ex vivo GSK-J4-pretreated DCs (Fig. 8B) . Probably, GSK-J4-treated DCs are able to affect RORgt and T-bet expression on CD4þ T cells, leading to a partial reduction in the number of IFN-gþIL-17þCD4þ T cells, as well as in the number of GM-CSFþCD4þ T cells in the brain of these mice. However, this effect is not strong enough to affect IFN-gþCD4þ T cells and IL-17þCD4þ T cells. On the other hand, because in EAE, DCs are in an inflammatory environment in which cytokines and metabolites needed for Treg differentiation are absent or in low concentrations [64e67], it is possible that they may be unable to promote differentiation to a Treg phenotype in vivo. This may explain the fact that no changes were observed in the frequencies of Tregs in vivo upon adoptive transfer of GSK-J4-treated DCs (Fig. 8C) . Moreover, no changes were observed in tolerogenic molecules in Tregs in vivo, suggesting that inhibition of Tregs generated by GSK-J4-treated DCs is independent of these markers and other tolerance molecules could be evaluated to understand how Tregs generated with GSK-J4 induce tolerance. However, it seems possible that the beneficial effects GSK-J4 on EAE might involve an increase in the suppressive function of Tregs trough DCs, as seen in our in vitro data as well as in our in vivo results on adoptive transference of Treg in EAE mice (Fig. 8E) . Thus, GSK-J4-treated DCs may be capable of maintaining a tolerogenic phenotype under inflammatory conditions, explained at least in part by an increase in the suppressive function of Tregs and a partial decrease in the CD4þIFN-gþIL-17þ and CMGSFþ inflammatory phenotypes and the consequent decrease in clinical score, despite its lack of effect on the Th1 and Th17 phenotypes.
Conclusion
The results presented herein indicate that GSK-J4 acts upon DCs, reducing the clinical course of EAE. We propose that systemic treatment with GSK-J4 or adoptive transfer of GSK-J4-treated DCs may be a promising approach for the treatment of autoimmune diseases, such as EAE. Moreover, our study is the first to demonstrate that H3K27me3 demethylase activity would act as a negative regulator of DC differentiation towards a tolerogenic phenotype.
